新型冠状病毒病2019的药物治疗与继发感染风险:单中心病例系列与叙述性综述
本文为单中心病例系列与叙述性综述,检索PubMed(建库至2021年3月)并手动筛选文献,评估ICU内COVID-19药物治疗对继发感染和临床结局的影响。纳入文献涉及COVID-19、SARS-CoV-2相关呼吸衰竭管理及药物治疗继发感染患病率。由于随访期短且研究间结果矛盾,托珠单抗和/或糖皮质激素的现有数据有限;对免疫反应在COVID-19中临床影响缺乏明确理解进一步复杂化免疫调节剂角色的认识。作者建议对接受免疫调节剂治疗的COVID-19患者延长试验和随访间隔。
要点
- 在ICU内接受托珠单抗和/或糖皮质激素治疗的COVID-19患者,现有数据因随访期短且研究结果矛盾而有限。
- 对免疫反应在COVID-19中临床影响缺乏明确理解,使免疫调节剂在继发感染风险中的角色难以确定。
- 基于现有文献,建议对接受免疫调节剂治疗的COVID-19患者延长试验和随访间隔。
- 本文为单中心病例系列与叙述性综述,检索PubMed至2021年3月,手动筛选文献。
适用人群与场景
- ICU内确诊COVID-19并接受药物治疗(托珠单抗和/或糖皮质激素)的患者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体药物剂量、给药途径、频次或目标值;仅提及托珠单抗和/或糖皮质激素作为免疫调节剂用于COVID-19管理。
- 基于现有文献,建议对接受免疫调节剂治疗的患者延长试验和随访间隔。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心病例系列与叙述性综述;样本量与中心数:单中心,样本量原文未提及。
- 干预与对照:评估托珠单抗和/或糖皮质激素等免疫调节剂对继发感染和临床结局的影响;对照原文未提及。
- 关键次要终点与不良事件:原文未提及具体数据;提及需关注继发感染风险。
证据类型、等级与局限
- 证据类型:单中心病例系列与叙述性综述;证据等级或推荐强度原文未提及。
- 局限:单中心、随访期短、研究间结果矛盾、对免疫反应临床影响缺乏明确理解;原文未提及样本量。
对床旁实践的改变
- 对ICU内接受托珠单抗和/或糖皮质激素治疗的COVID-19患者,应延长试验和随访间隔以评估继发感染与临床结局。
- 原文未提及对具体用药方案或人群适用性的改变;常见陷阱为因随访期短而低估继发感染风险。
指南或共识出处
- 原文未提及具体指南或共识名称;文献检索来源为PubMed(建库至2021年3月)。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Since the onset of the coronavirus disease 2019 pandemic, immune modulators have been considered front-line candidates for the management of patients presenting with clinical symptoms secondary to severe acute respiratory syndrome coronavirus 2 infection. Although heavy emphasis has been placed on early clinical efficacy, we sought to evaluate the impact of pharmacologic approach to coronavirus disease 2019 within the ICU on secondary infections and clinical outcomes.
DATA SOURCES: PubMed (inception to March 2021) database search and manual selection of bibliographies from selected articles.
STUDY SELECTION AND DATA EXTRACTION: Articles relevant to coronavirus disease 2019, management of severe acute respiratory syndrome coronavirus 2-associated respiratory failure, and prevalence of secondary infections with pharmacotherapies were selected. The MeSH terms "COVID-19," "secondary infection," "SARS-CoV-2," "tocilizumab," and "corticosteroids" were used for article identification. Articles were narratively synthesized for this review.
DATA SYNTHESIS: Current data surrounding the use of tocilizumab and/or corticosteroids for coronavirus disease 2019 management are limited given the short follow-up period and conflicting results between studies. Further complicating the understanding of immune modulator role is the lack of definitive understanding of clinical impact of the immune response in coronavirus disease 2019.
CONCLUSIONS: Based on the current available literature, we suggest prolonged trials and follow-up intervals for those patients managed with immune modulating agents for the management of coronavirus disease 2019.
参考来源
- Behal M, Barlow B, Mefford B, et al. Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review. Crit Care Explor. 2021. PMID: 34278319. doi:10.1097/CCE.0000000000000492
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。